Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Urinary microbiota characterization of superficial bladder Cancer patients undergoing BCG immunotherapy

Funder: São Paulo Research Foundation

Funding period
0
Funding amount
Abstract
Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (NMIBC) accounts for 70-80% of all Bladder Cancer initial diagnoses. The standard treatment for NMIBC involves transurethral resection of the tumor, followed by intravesical immunotherapy with BCG. The clinical benefits of BCG therapy have been extensively documented. However, only 50% of the patients have long-lasting benefit, whereas the remaining patients present disease recurrence and progression following treatment. Furthermore, due to either local or systemic adverse events, between 5 and 20% of BCG-treated patients present intolerance to therapy during its distinct phases. Therefore, the identification of biomarkers for predicting clinical benefit and toxicity to BCG therapy is instrumental for a personalized management of Bladder Cancer patients. Recent studies highlighted the relevance of the gut microbiota composition for the efficacy of immune checkpoint blockade immunotherapy in Cancer patients and its direct association with treatment-related adverse events. These studies underlie the potential of the microbiota as a predictive biomarker of BGC response and toxicity. Interestingly, there is no data on the association between the urinary microbiota composition and BCG treatment outcome and toxicity in Bladder Cancer patients. In this study, we intend to characterize the urinary microbiota of superficial Bladder Cancer patients using metagenomics analysis of urinary samples collected before treatment and evaluate the relationship between microbiota composition, the occurrence of adverse events and BCG clinical benefit. This will allow the identification of predictive biomarkers of toxicity and clinical benefit to guide treatment of NMIBC patients. These studies may also provide a better understanding of the, not yet fully elucidated, mechanism of action of BCG therapy, enabling the development of new therapeutic approaches. (AU)
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

European Commission

USD 2,452,885
2020 - 2022

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Immunization

  • RCDC

    Patient Safety

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • HRCS RAC

    5.1 Pharmaceuticals

  • HRCS RAC

    6.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science